Abstract:Abstract Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale 1–3 . Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4–5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter 4 ; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation 5,6 ; analyses timings and patterns of tumour evolution 7 ; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity 8,9 ; and evaluates a range of more-specialized features of cancer genomes 8,10–18 .

Current and future trends in whole genome sequencing in cancer

Cancer whole-genome sequencing: present and future

[Whole-genome sequencing: a new approach for understanding of pathogenesis and individualized treatment of cancer].

Whole genome sequencing analysis for cancer genomics and precision medicine

Emerging Trends in Clinical Cancer Genomic Research.

The role of genomics in global cancer prevention

Genomic Sequencing for Cancer Diagnosis and Therapy.

State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response

The Challenge for Precision Medicine: All Tumor Genomes Are Different and All Cancer Patients Are Different in Their Own Way

Cancer cytogenetics in a genomics world: Wedding the old with the new

Recent Trends in Cancer Genomics and Bioinformatics Tools Development

Cancer treatment comes to age: from one-size-fits-all to next-generation sequencing (NGS) technologies

The Development of Cancer Genome Research and Its Clinical Opportunity Brought by Next Generation Sequencing

Global mapping of cancers: The Cancer Genome Atlas and beyond

Pan-cancer analysis of whole genomes

Comprehensive Fundamental Somatic Variant Calling and Quality Management Strategies for Human Cancer Genomes

Single Cell Sequencing: A New Dimension in Cancer Diagnosis and Treatment

Thyroid cancer under the scope of emerging technologies

Clinical application of whole-genome sequencing for precision oncology of solid tumors

Unveiling the pan-cancer landscape of S100A16: A comprehensive analysis of prognostic significance, drug sensitivity, and immunomodulatory roles

Harnessing cancer genomes for precision oncology